Radium-223 chloride: Radiation safety, tolerability, and survival gain in patients with castration-resistant prostate cancer (CRPC) and bone metastases

被引：0
|
作者：
Lewington, Valerie [1 ]
Lamey, Roy [2 ]
Staudacher, Karin [3 ]
Vogelzang, Nicholas [2 ]
机构：
[1] Guys & St Thomas Hosp, London, England
[2] Comprehens Canc Ctr Nevada, US Oncol Res, Las Vegas, NV USA
[3] Algeta ASA, Oslo, Norway
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
222
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The Timing of Radium-223 Therapy in Castration-Resistant Prostate Cancer
    Sartor, Oliver
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 570 - 572
  • [32] The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases
    Ram, Prasanna
    Mandal, Swarnendu
    Das, Manoj K.
    Nayak, Prasant
    PROSTATE, 2023, 83 (06): : 613 - 613
  • [33] The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases
    Liu, Alex J.
    Kosiorek, Heidi E.
    Ueberroth, Benjamin E.
    Jaeger, Ellen
    Ledet, Elisa
    Kendi, Ayse T.
    Tzou, Katherine
    Quevedo, Fernando
    Choo, Richard
    Moore, Cassandra N.
    Ho, Thai H.
    Singh, Parminder
    Keole, Sameer R.
    Wong, William W.
    Sartor, Oliver
    Bryce, Alan H.
    PROSTATE, 2022, 82 (12): : 1202 - 1209
  • [34] Radium-223 chloride, a first-in-class alpha-pharmaceutical for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Biodistribution/dosimetry compared to overall safety profile.
    Lewington, V.
    Parker, C.
    Hindorf, C.
    Flux, G.
    Chittenden, S.
    Sgouros, G.
    O'Bryan-Tear, G.
    Aksnes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] RADIUM-223 DICHLORIDE (RADIUM-223) FOR THE TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND SYMPTOMATIC BONE METASTASES: THE ESSENTIAL ROLE OF NURSES IN PATIENT CARE AND MANAGEMENT
    Curley, Tracy
    Arauz, Gabrielle
    Jensen, Trine
    Wahba, Mona
    Delacruz, Anthony
    ONCOLOGY NURSING FORUM, 2014, 41 (02) : E115 - E115
  • [36] Safety and efficacy of radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
    Uemura, Hirotsugu
    Uemura, Hiroji
    Matsubara, N.
    Kaneko, M.
    Doi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S489 - S489
  • [37] RADIUM-223: TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    James, D.
    Hillery, R.
    Freeman, L.
    Kumari, A.
    Kearney, N.
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 30 - 31
  • [38] Radium-223 In The Treatment Of Metastatic Castration-Resistant Prostate Cancer
    Vazzana, C.
    Morano, S.
    Di Lascio, A.
    Grana, C.
    Chinol, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S880 - S880
  • [39] Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Cho, Steve Y.
    Pandit-Taskar, Neeta
    Jacene, Heather
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
    Prelaj, Arsela
    Rebuzzi, Sara Elena
    Buzzacchino, Federica
    Pozzi, Chiara
    Ferrara, Carla
    Frantellizzi, Viviana
    Follacchio, Giulia Anna
    Civitelli, Liana
    De Vincentis, Giuseppe
    Tomao, Silverio
    Bianco, Vincenzo
    ONCOLOGY LETTERS, 2019, 17 (02) : 1467 - 1476
12345